Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stephen J. Gatto
AddedFeb 15, 2024
UpdatedMay 31, 2026
Stephen J. Gatto

Stephen J. Gatto

Board Member, Entrinsic Bioscience

CrunchbaseLinkedInThe Org

Stephen J. Gatto's Career

Entrinsic Bioscience
Entrinsic Bioscience

Norwood, MA, US

Board Member· Board
GC Innovation America
GC Innovation America

Houston, TX, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stephen J. Gatto's Career

Entrinsic Bioscience
Entrinsic Bioscience
Series D$58.2M382014Norwood, MA, US
Board Member· Board

Leadership at Entrinsic Bioscience

Paul OkunieffPaul OkunieffCo-Founder
Sadasivan VidyasagarSadasivan VidyasagarCo-Founder

Similar to Entrinsic Bioscience

VymedicVymedicEnglewood, CO, USTherapeuticsest. 2020VymedicEnglewood, CO, US · est. 2020

Vymedic: A biotech leader in amino acid-based therapeutics for health support and wellness maintenance.

Pre-Seed · $525k74
Elysium HealthElysium HealthNew York City, NY, USHealth Supplementsest. 2014Elysium HealthNew York City, NY, US · est. 2014

Elysium Health, a NYC-based life sciences company, offers metabolic repair and optimization medicines in the US.

Series C · $71.2M83
BioHealthonomicsBioHealthonomicsSanta Monica, CA, USBiotech, Pharmaceuticalsest. 1905BioHealthonomicsSanta Monica, CA, US · est. 1905

BioHealthonomics: An R&D biotech firm innovating treatments for migraines, PD, and AD.

Angel · $35.8k5
AobiomeAobiomeCambridge, MA, USBiotherapeuticsest. 2013AobiomeCambridge, MA, US · est. 2013

AOBiome: A U.S. biotech firm innovating health through ammonia-oxidizing bacteria-based products.

Series C · $38.7M15
GC Innovation America
GC Innovation America
Public$110M752005Houston, TX, US
Co-Founder

Leadership at GC Innovation America

Dennis McCulloughDennis McCulloughCEO
Lonnie IngramLonnie IngramCo-Founder

Similar to GC Innovation America

GenomaticaGenomaticaSan Diego, CA, USBiomanufacturing, Chemicalsest. 2000GenomaticaSan Diego, CA, US · est. 2000

San Diego-based Genomatica develops and licenses biological manufacturing processes for chemical production.

Late Stage Private · $340.3M175
GlycoSurfGlycoSurfSalt Lake City, UT, USChemicalsest. 2013GlycoSurfSalt Lake City, UT, US · est. 2013

Specialty chemical manufacturer with a focus on eco-friendly surfactants.

Pre-Seed · $4.9M8
GevoGevoEnglewood, CO, USBiofuels, Chemicalsest. 2005GevoEnglewood, CO, US · est. 2005

Gevo Inc.: A technology leader in renewable chemicals, advanced biofuels, and green diesel/jet fuels.

Public · $578.7M99
AmyrisAmyrisEmeryville, CA, USChemicals, Ingredientsest. 2003AmyrisEmeryville, CA, US · est. 2003

Amyris, Inc.: Global producer and distributor of sustainable synthetic ingredients for diverse markets.

Public · $1.9B1.6k

Stephen J. Gatto's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Stephen J. Gatto

Andy OlsonAndy OlsonCo-Founder · Inherent BiosciencesMark WestermanMark WestermanCEO · Intrinsic LifeSciencesYadin ShemmerYadin ShemmerFounder · IntrinsicMr. Cary P. HaganMr. Cary P. HaganCEO · Barricaid